Navigation Links
BioTrends Announces a New Syndicated Report Series, LaunchTrends(TM): Feraheme
Date:7/1/2009

EXTON, Pa., July 1 /PRNewswire/ -- In conjunction with yesterday's FDA approval of AMAG Pharmaceuticals' Feraheme (ferumoxytol), BioTrends Research Group, Inc. is pleased to announce LaunchTrends(TM): Feraheme, a syndicated report series that will track the trial, adoption and usage of Feraheme. Feraheme is a new IV Iron product approved to treat iron deficiency anemia in patients with Chronic Kidney Disease, both on and not on dialysis. Surveys will be fielded at one month, three months, and six months post launch. Each report consists of findings from a quantitative survey with 50 Nephrologists and qualitative interviews with a subset of the survey respondents.

BioTrends has been following Feraheme in its TreatmentTrends(R): US Nephrology reports since the end of 2006. According to the most recent TreatmentTrends(R) survey, interest in the product is high, particularly in the CKD-ND setting, although Nephrologists predict uptake across all patient types.

LaunchTrends(TM) measure launch effectiveness of new products from FDA approval through six months post launch. The first wave of the LaunchTrends(TM): Feraheme report series will be fielded in mid-August, measuring uptake at one month. Topline findings will be available shortly thereafter and the full report will follow in mid-September.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To purchase this report or to learn more about BioTrends' syndicated publications, please contact us at (610) 363-3872 or visit us at www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Product Shifts are Occurring in the Renal Anemia and Bone and Mineral Metabolism Markets According to the Most Recent TreatmentTrends(R): US Nephrology Report from BioTrends Research Group
2. New Report by BioTrends Research Group to Highlight the Launch of SIMPONI(R) (golimumab)
3. BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis
4. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
5. New York Citys World Product Centre Announces Initial Charter Partners
6. Ingenious Med Announces a New Coding & Compliance Tool, MasterCoder
7. Nielsen Announces First-Ever CLIO Healthcare Awards Now Accepting Entries
8. Industry Leader Announces Next Generation of Patient Flow Automation
9. HealthMEDX Announces Vision Solution
10. eDiets.com(R) Announces Meal Delivery Marketing Partnership With Golds Gym Franchise Network
11. Aftercad Announces Signup for the 3D Workspace Beta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at ... company to wait until March 2017 for an interest rate increase, according to Rajeev ... of Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... with discovery of thousands of defective respirators, according to court documents and SEC ... case of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, ... as a partner for the Tamika Catchings Legacy Tour that will commemorate ... leader in hardwood basketball surfaces in all forms and levels of the game, Connor ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced two key appointments and ... continued investment and strategic growth plans in the Asia Pacific region. , Howard ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
Breaking Medicine Technology: